Furthermore, our univariate analysis identified WHO grade and TMUB1 expression as significant predictors of overall survival, highlighting the potential of TMUB1 as a promising biomarker and therapeutic target in the challenging landscape of glioma, with implications for risk stratification and personalized treatment approaches. Here, TMUB1 is linked to central nervous system cancer.